This is an article I have long been thinking about and researching. You could consider my previous article a prequel which was published in December under the title "If Robotaxi Is The Next Frontier, Either Tesla Or Google Is Completely Mispriced".I’m a long-term growth and dividend-growth investor covering both US and European equity markets. I seek undervalued stocks and high-quality dividend growers that generate dependable cash flow for reinvestment. I share one of my portfolios on eToro where I qualifi ...

If you want to own Intuitive Machines stock, you're going to need a lot of patience. Something curious is happening with Intuitive Machines (LUNR 5.79%) stock, the tiny lunar exploration company that last year landed a U.S. spacecraft on the moon for the first time in over 50 years. Yesterday, Bank of America analyst Ronald Epstein lowered his price target on Intuitive stock from $16 to $10.50, below where the stock was trading, triggering an "underperform" rating. And yet, Intuitive Machines stock went up, ...

Group Overview - IBA reported a solid start to 2025, driven by strong market momentum in Proton Therapy and positive trends in Dosimetry [4][6] - The company has a backlog of €1.5 billion in IBA Clinical Equipment and Services, with a positive net cash position of €9 million [6] - A share buyback program is ongoing, with 582,849 shares purchased as of May 19, 2025, against a target of 650,000 by year-end [6] Proton Therapy and Dosimetry - There are currently 38 ongoing proton therapy projects, including 8 ProteusPLUS and 30 ProteusONE systems, with 9 installations underway [7] - Strong commercial activity is noted in the Asia-Pacific region, with significant contracts signed in India and Taiwan [7] - The integration of Radcal Corporation is back on track, supporting profitability in Dosimetry [7] Product Innovations - IBA launched the QUASAR GRID system and myQA Blue Phantom, enhancing quality assurance solutions [7] - Two additional sales in Radio Pharma Solutions were activated post-period, including a contract in Taiwan [7] - The company introduced CASSY, a new compact synthesizer aimed at improving efficiency in radiotracers production [7] Financial Outlook - IBA maintains its one-year guidance for 2025, expecting a REBIT of at least €25 million, supported by positive performance in Proton Therapy [9] - The mid-term outlook (2024-2028) indicates confidence in sustained profitability while monitoring macroeconomic conditions [10] - Revenue is projected to grow at a normalized frontloaded rate of 5-7% CAGR, with OPEX expected to be up to 30% of sales per annum [14]